US 12,433,836 B2
Parenterally administered immune enhancing drugs
Juan Carlos Jaen, Burlingame, CA (US); Jenna Leigh Jeffrey, Oakland, CA (US); Lixia Jin, San Mateo, CA (US); Jaroslaw Kalisiak, Mountain View, CA (US); Joyson J. Karakunnel, Potomac, MD (US); Kenneth V. Lawson, San Francisco, CA (US); Manmohan Reddy Leleti, Dublin, CA (US); and Jay Patrick Powers, Pacifica, CA (US)
Assigned to ARCUS BIOSCIENCES, INC., Hayward, CA (US)
Appl. No. 16/978,920
Filed by ARCUS BIOSCIENCES, INC., Hayward, CA (US)
PCT Filed Mar. 8, 2019, PCT No. PCT/US2019/021300
§ 371(c)(1), (2) Date Sep. 8, 2020,
PCT Pub. No. WO2019/173682, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/700,548, filed on Jul. 19, 2018.
Claims priority of provisional application 62/641,003, filed on Mar. 9, 2018.
Prior Publication US 2020/0405629 A1, Dec. 31, 2020
Int. Cl. A61K 9/00 (2006.01); A61K 31/7076 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)
CPC A61K 9/0019 (2013.01) [A61K 31/7076 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 27 Claims
 
1. A method of treating cancer in a subject in need thereof, said method comprising administering a therapeutically effective amount of a compound having the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered intravenously to the subject as a single dose every two weeks, three weeks, or four weeks, and wherein the therapeutically effective amount maintains a plasma concentration (Css) of at least 90 ng/mL for a period of 7 days or more.